Drug Type Monoclonal antibody |
Synonyms AB-sCLU mAB, Anti-clusterin monoclonal antibody, 16B5 + [2] |
Target |
Mechanism CLU inhibitors(Clusterin inhibitors), Immunomodulators |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
colon cancer liver metastasis | Phase 2 | CA | 15 Feb 2024 | |
Metastatic Colorectal Carcinoma | Phase 2 | CA | 15 Feb 2024 | |
metastatic non-small cell lung cancer | Phase 2 | US | 23 Feb 2021 | |
metastatic non-small cell lung cancer | Phase 2 | CA | 23 Feb 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 01 Apr 2015 | |
Neoplasms | Discovery | RU | 29 May 2013 |
NCT04364620 (ASCO2024) Manual | Phase 2 | 35 | wfztpxysbb(jwicbyoubi) = wzwertjvso mgdhbkqlrd (dgibqcxzlq ) View more | Positive | 24 May 2024 | ||
NCT02412462 (AACR2017) Manual | Phase 1 | 15 | dlmiziesxp(bdjdehgoym) = 5 were reported (sepsis, pyrexia, dyspnea, intra-abdominal hemorrhage and main stem bronchus obstruction), none of which were judged related to the study treatment fvwdbidxde (xsdcfuxkji ) View more | Positive | 01 Jul 2017 |